TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04082520

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Gallium Ga 68-DOTATATE
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lutetium Lu 177 Dotatate
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo PET/MRI

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Undergo PET/MRI

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo PET/CT and/or SPECT/CT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single Photon Emission Computed Tomography
Description: Undergo SPECT/CT
Study: NCT01065051

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riociguat (Adempas, BAY63-2521)
Description: 1 mg single oral dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single oral dose
Study: NCT02465749

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Continuous oxygen
Description: Continuous oxygen intake at a concentration of 93±3%, 3L/min flow-rate, 2h/bid, five days a week;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Continuous oxygen
Description: Continuous oxygen intake at a concentration of 93±3%, 3L/min flow-rate, 2h/bid, five days a week;

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: blue light-absorbing sunglasses
Description: Wearing blue light-absorbing sunglasses at daily time;

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: blue light-absorbing sunglasses
Description: Wearing blue light-absorbing sunglasses at daily time;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Compound thrombosis capsule sig: 1.5g/tid
Description: Compound thrombosis capsule sig: 1.5g/tid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Compound thrombosis capsule sig: 1.5g/tid
Description: Compound thrombosis capsule sig: 1.5g/tid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Compound thrombosis capsule sig: 1.5g/tid
Description: Compound thrombosis capsule sig: 1.5g/tid

Intervention type: DRUG
Group type: OTHER
Intervention: Compound thrombosis capsule sig: 1.5g/tid
Description: Compound thrombosis capsule sig: 1.5g/tid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba pills sig: 300mg/tid;
Description: Ginkgo biloba pills sig: 300mg/tid;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba pills sig: 300mg/tid;
Description: Ginkgo biloba pills sig: 300mg/tid;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ginkgo biloba pills sig: 300mg/tid;
Description: Ginkgo biloba pills sig: 300mg/tid;

Intervention type: DRUG
Group type: OTHER
Intervention: Ginkgo biloba pills sig: 300mg/tid;
Description: Ginkgo biloba pills sig: 300mg/tid;

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin B sig: 10mg/tid
Description: Vitamin B sig: 10mg/tid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin B sig: 10mg/tid
Description: Vitamin B sig: 10mg/tid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin B sig: 10mg/tid
Description: Vitamin B sig: 10mg/tid

Intervention type: DRUG
Group type: OTHER
Intervention: Vitamin B sig: 10mg/tid
Description: Vitamin B sig: 10mg/tid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin AD sig: 1 tablet/tid
Description: Vitamin AD sig: 1 tablet/tid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin AD sig: 1 tablet/tid
Description: Vitamin AD sig: 1 tablet/tid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin AD sig: 1 tablet/tid
Description: Vitamin AD sig: 1 tablet/tid

Intervention type: DRUG
Group type: OTHER
Intervention: Vitamin AD sig: 1 tablet/tid
Description: Vitamin AD sig: 1 tablet/tid
Study: NCT03811847

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate Extended Release Oral Capsule
Description: Stimulant It can treat ADHD and narcolepsy.~1 capsule 18mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate Extended Release Oral Capsule
Description: Stimulant It can treat ADHD and narcolepsy.~1 capsule 18mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate Extended Release Oral Capsule
Description: Stimulant It can treat ADHD and narcolepsy.~1 capsule 18mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate Extended Release Oral Capsule
Description: Stimulant It can treat ADHD and narcolepsy.~1 capsule 18mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate Extended Release Oral Capsule
Description: Stimulant It can treat ADHD and narcolepsy.~1 capsule 18mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate Extended Release Oral Capsule
Description: Stimulant It can treat ADHD and narcolepsy.~1 capsule 18mg

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo comparator MPH Matched Placebo Tablet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo comparator MPH Matched Placebo Tablet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo comparator MPH Matched Placebo Tablet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo comparator MPH Matched Placebo Tablet
Study: NCT03456674

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LaseMD System
Description: A non-invasive fractional thulium laser delivering a wavelength of light energy as a fractionated array of microbeams to be absorbed by and damage the target molecule, a chromophore.
Study: NCT00434655

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic restrictive procedure
Description: Morbidly Obese VETERANS will receive one of two laparoscopic bariatric restrictive procedures.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic restrictive procedure
Description: Morbidly Obese VETERANS will receive one of two laparoscopic bariatric restrictive procedures.
Study: NCT04184921

Intervention type: DRUG
Intervention: Osimertinib 80 MG
Description: Osimertinib, also known as azd9291, is a 3rd-generation EGFR-TKI used to treat NSCLC patients with resistance to 1st generation EGFR-TKI due to T790M mutation. It has been approved in clinical applications by the FDA in 2015.

Intervention type: DRUG
Intervention: Osimertinib 80 MG
Description: Osimertinib, also known as azd9291, is a 3rd-generation EGFR-TKI used to treat NSCLC patients with resistance to 1st generation EGFR-TKI due to T790M mutation. It has been approved in clinical applications by the FDA in 2015.
Study: NCT03669263

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl buccal soluble film (FBSF)
Description: After screening, eligible subjects were individually titrated to an adequate dose of FBSF (titration period) and continued on this dose as required to control their BTP throughout the maintenance period of the study.~During the dose titration period, subjects were administered with FBSF in a dose escalation manner until a treatment dose was identified (defined as an adequate relief of BTP observed for at least two consecutive episodes). All patient started with a dose of 200 μg and increased by 200 μg in each subsequent episode until an adequate pain relief with tolerable side effects was achieved. Doses above 1200 μg were not allowed.
Study: NCT03819504

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 4-D navigated stereotactic radio surgical ablation
Description: 4-D navigated stereotactic radio surgical ablation will be performed in patients with structural heart disease and sustained monomorphic ventricular tachycardia/tachycardias
Study: NCT01481259

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous cytokine-induced killer cell
Description: Subjects receive autologous cytokine-induced killer cell infusion every 21 days in the absence of disease progression or unacceptable toxicity.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Subjects receive pemetrexed infusion at a dose of 500mg/m2 every 21 days in the absence of disease progression or unacceptable toxicity.
Study: NCT01584427

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Healthy Carbohydrate Diet vs. Western Style Diet
Description: Cross over study with two intervention diets. Healthy Carbohydrate Diet with approximally 55 g of dietary fibers (arabinoxylan and resistant starch)compared with western style diet with low content of dietary fibers.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Healthy Carbohydrate Diet vs. Western Style Diet
Description: Cross over study with two intervention diets. Healthy Carbohydrate Diet with approximally 55 g of dietary fibers (arabinoxylan and resistant starch)compared with western style diet with low content of dietary fibers.
Study: NCT02881151

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep brain stimulation
Description: Delivery of continuous, low-voltage electrical pulses to deep portions of the brain via an implantable pacemaker-like device.
Study: NCT04780594

Intervention type: PROCEDURE
Intervention: The study evaluates all surgical patients operated, both elective scheduled and emergent cases
Description: Administrative database was automatically collected. That included demographic, clinical antecedents, surgical team and surgical procedure, primary and secondary diagnoses and principal and secondary surgical procedures. A case-mix grouping system administrative automatic recorded based on the ICD-10-AM International Classification of Diseases. According to the Diagnoses-related Groups (DRG's). the Severity of Illness Index assigns to each patient an overall severity score (from 1 to 4) and mortality risk score (from 1 to 4)

Intervention type: PROCEDURE
Intervention: The study evaluates all surgical patients operated, both elective scheduled and emergent cases
Description: Administrative database was automatically collected. That included demographic, clinical antecedents, surgical team and surgical procedure, primary and secondary diagnoses and principal and secondary surgical procedures. A case-mix grouping system administrative automatic recorded based on the ICD-10-AM International Classification of Diseases. According to the Diagnoses-related Groups (DRG's). the Severity of Illness Index assigns to each patient an overall severity score (from 1 to 4) and mortality risk score (from 1 to 4)
Study: NCT00403689

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beta-D-Glucan
Description: 1,5 g Beta-D-Glucan daily

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 1.5 g waxy maize starch daily
Study: NCT03453346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: Generic sofosbuvir tablet 400 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Ribavirin was provided in 100-mg tablets.
Study: NCT03811847

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo comparator MPH Matched Placebo Tablet

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo comparator MPH Matched Placebo Tablet
Study: NCT01429428

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Far-IR compression stockings
Description: The far-IR side of compression stocking will be used by subjects, during the day, for six hours a day, during 90 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: No far-IR compression stockings
Description: This side of compression stocking without far-IR radiation will be used by subjects, during the day, for six hours a day, during 90 days.
Study: NCT02286934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol
Description: * Day 1 to 3 : Carvedilol 12.5 mg qd~* Day 4 to 8 : Carvedilol 25 mg qd~* Day 9 to 11 : Carvedilol 12.5 mg qd

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Isoproterenol Sensitivity Test
Description: Day 0, 1, 8 : Isoproterenol Sensitivity Test
Study: NCT00571246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate
Description: Participants are randomized to take Topiramate (250mg/day) 2 times a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lamotrigine
Description: Participants are randomized to take Lamotrigine (250 mg/day) 2 times a day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants are randomized to take placebo
Study: NCT03217370

Intervention type: OTHER
Group type: OTHER
Intervention: education of guidelines
Description: * Guidelines will be updated and education will be given to haematologists in several ways.~* ICT implementations: a) last result of haemoglobin and platelet count will be shown on the electronic blood order; b) an electronical clinical decision support system will be implemented to order blood components
Study: NCT00003671

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: asparaginase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: daunorubicin hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mercaptopurine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thioguanine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Study: NCT02908685

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered orally (via mouth) or through a feeding tube (naso-gastric or gastrostomy tube).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered orally (via mouth) or through a feeding tube (naso-gastric or gastrostomy tube).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered orally (via mouth) or through a feeding tube (naso-gastric or gastrostomy tube).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Risdiplam
Description: Risdiplam will be administered orally (via mouth) or through a feeding tube (naso-gastric or gastrostomy tube).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risdiplam
Description: Risdiplam will be administered orally (via mouth) or through a feeding tube (naso-gastric or gastrostomy tube).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Risdiplam
Description: Risdiplam will be administered orally (via mouth) or through a feeding tube (naso-gastric or gastrostomy tube).
Study: NCT04447079

Intervention type: BEHAVIORAL
Intervention: Assertive Community Treatment (ACT)
Description: Assertive Community Treatment (ACT) is part of a 6-month program ARFAs will undergo.~ACT teams will engage with ARFAs on a dedicated schedule. Each visit would last an average of 60 minutes. There will not be a re-arrangement of no-show visits. ACT teams will re-engage the ARFA over the phone to plan for the next visit as per the schedule.~In keeping with principles of ACT, ARFA's will be assertively sought out in the community and provided intensive engagement, with holistic and supportive care alongside a harm reduction approach. Care will also involve case management and involvement of SSA's.~Each interaction during the treatment period will focus on various aspects covering physical health, mental health, and addiction
Study: NCT02908685

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risdiplam
Description: Risdiplam will be administered orally (via mouth) or through a feeding tube (naso-gastric or gastrostomy tube).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Risdiplam
Description: Risdiplam will be administered orally (via mouth) or through a feeding tube (naso-gastric or gastrostomy tube).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risdiplam
Description: Risdiplam will be administered orally (via mouth) or through a feeding tube (naso-gastric or gastrostomy tube).
Study: NCT02057094

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Protein, High-Protein, and Control

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Protein, High-Protein, and Control

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Protein, High-Protein, and Control
Study: NCT01211353

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Personalized Drinking Feedback
Description: Personalized feedback about one's drinking habits

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Education-Only
Description: Educational information about alcohol use
Study: NCT01046604

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lovaza group
Description: Patients who are scheduled for mitral valve repair surgery at least 3 weeks removed from the initial consult will be recruited to take 4 capsules of Lovaza (omega 3 fatty acids) daily, for 3 weeks prior to their surgery.
Study: NCT02333682

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 25(OH)D3 (Calcifediol Hy.D) 10 mcg
Description: 25(OH)D3 (Calcifediol Hy.D)

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 25(OH)D3 (Calcifediol Hy.D) 15 mcg
Description: 25(OH)D3 (Calcifediol Hy.D)
Study: NCT02064517

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: MTA
Description: Creation of a barrier apicale in the MTA

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hydroxide of calcium
Description: Revascularisation pulpaire with some hydroxide of calcium
Study: NCT02333682

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 25(OH)D3 (Calcifediol Hy.D) 20 mcg
Description: 25(OH)D3 (Calcifediol Hy.D)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3 (Cholecalciferol) 20 mcg
Description: Vitamin D3 (Cholecalciferol)
Study: NCT02608775

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Metrodoloris Medical System
Description: Application of a skin electrode

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Metrodoloris Medical System
Description: Application of a skin electrode

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aisys® care station, Acertys
Description: Standard photoplethysmography

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aisys® care station, Acertys
Description: Standard photoplethysmography
Study: NCT03666507

Intervention type: PROCEDURE
Intervention: Intraoperative Monitoring during resection of brain tumor
Description: Intraoperative Monitoring during resection of brain tumor

Intervention type: PROCEDURE
Intervention: Intraoperative Monitoring during resection of brain tumor
Description: Intraoperative Monitoring during resection of brain tumor
Study: NCT02241057

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational Air-Activated Adhesive-Backed Heat Patch (3-Cell)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Investigational Air-Activated Adhesive-Backed Heat Patch (3-Cell)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Temperature Probe
Study: NCT03344107

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: USSQ questionnaire administration after RIRS.
Description: USSQ symptoms questionnaire administration after RIRS

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: USSQ questionnaire administration after RIRS.
Description: USSQ symptoms questionnaire administration after RIRS
Study: NCT03676543

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Timed repetitive sensory stimulation
Description: Timed repetitive sensory stimulation (TRSS) will be applied at the onset or during seizures
Study: NCT01084278

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: Colchicine tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: Colchicine tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: Colchicine tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: Colchicine tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: Colchicine tablets
Study: NCT03075722

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Saturn nasal mask
Description: Nasal mask for the treatment of obstructive sleep apnea (OSA)
Study: NCT01846195

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CM 1500

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: CM 1500
Study: NCT03433820

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Observation of wound healing
Description: Observation of wound healing after skin biopsy
Study: NCT03060395

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: A2 milk 100
Description: Days 1 and 2: 100 mL A2 milk twice a day

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: A2 milk 150
Description: Days 3 and 4: 150 mL A2 milk twice a day

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: A2 milk 200
Description: Days 5 and 6: 200 mL A2 milk twice a day

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: A2 milk 250
Description: Days 7 to 14: 250 mL A2 milk twice a day

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: A1/A2 milk 100
Description: Days 1 and 2: 100 mL A1/A2 milk twice a day

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: A1/A2 milk 150
Description: Days 3 and 4: 150 mL A1/A2 milk twice a day

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: A1/A2 milk 200
Description: Days 5 and 6: 200 mL A1/A2 milk twice a day

Intervention type: DIETARY_SUPPLEMENT
Group type: SHAM_COMPARATOR
Intervention: A1/A2 milk 250
Description: Days 7 to14: 250 mL A1/A2 milk twice a day
Study: NCT02860624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 mg ilaprazole
Description: Two 5-mg ilaprazole tablets (Livzon Pharm Group Inc., China) being taken orally each morning on an empty stomach for 8 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 40mg esomeprazole
Description: One 20-mg omeprazole capsule (AstraZeneca, Losec) being taken orally each morning on an empty stomach for 8 weeks
Study: NCT01728077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam
Description: Flexible dosing, can up and down-titrate as needed.